
BeiGene Ltd (ONC) Stock Forecast & Price Target
BeiGene Ltd (ONC) Analyst Ratings
Bulls say
BeOne Medicines is a promising biotech company with a strong financial outlook, thanks to its highly successful commercialized drug Brukinsa which makes up for 74% of the company's total revenue. With a diverse and active pipeline, the company is well-positioned to continue its success in the highly competitive market, competing with major players such as AbbVie and AstraZeneca. However, potential risks in the industry, such as competition and regulatory challenges, should be carefully monitored for any potential impact on the company's growth.
Bears say
BeOne Medicines is showing promising solid tumor assets at the ASCO event, with a global leadership in Brukinsa and two other approved drugs generating revenue mainly in China. While facing competition from AbbVie and AstraZeneca, the company has over 50 drugs in clinical trials in its active pipeline, supporting its potential for success in the coming years. However, risks to consider include commercial, pipeline/regulatory, reimbursement, and competitive risks, which may impact its valuation.
This aggregate rating is based on analysts' research of BeiGene Ltd and is not a guaranteed prediction by Public.com or investment advice.
BeiGene Ltd (ONC) Analyst Forecast & Price Prediction
Start investing in BeiGene Ltd (ONC)
Order type
Buy in
Order amount
Est. shares
0 shares